BioCentury | Feb 22, 2019
Financial News

Peloton planning Phase III kidney cancer study with $150M series E

...Musso CFO. The company said Musso previously led IPOs at Bellicum Pharmaceuticals Inc. (NASDAQ:BLCM) and Targacept Inc....
BioCentury | Feb 20, 2019
Financial News

Peloton planning Phase III kidney cancer study with $150M series E

...Musso CFO. The company said Musso previously led IPOs at Bellicum Pharmaceuticals Inc. (NASDAQ:BLCM) and Targacept Inc....
BioCentury | May 4, 2018
Financial News

Attenua raises $35M series A

...neuronal nicotinic acetylcholine receptor alpha 7 (CHRNA7) agonist from Catalyst Biosciences Inc. (NASDAQ:CBIO) in 2016. Targacept Inc....
BioCentury | Apr 30, 2018
Financial News

Cough company Attenua raises $35M series A, names CEO

...neuronal nicotinic acetylcholine receptor alpha 7 (CHRNA7) agonist from Catalyst Biosciences Inc. (NASDAQ:CBIO) in 2016. Targacept Inc....
BioCentury | Oct 31, 2016
Company News

Catalyst Biosciences deal

...the products when it merged with Targacept Inc. , declined to disclose further details. Last year, Targacept...
BioCentury | Aug 22, 2016
Company News

Catalyst Biosciences, Attenua deal

...in milestones, plus royalties. Catalyst gained the products when it merged with Targacept Inc. last year. Targacept...
...treat schizophrenia and missed the primary endpoint in a Phase II trial to treat ADHD. Targacept...
...endpoint in a Phase II trial to treat Type II diabetes. Under a 2013 deal, Targacept...
BioCentury | Sep 9, 2015
Financial News

Selecta raises $38M in series E

...Particle (SVP) platform. Also on Tuesday, Selecta named Earl Sands CMO. Sands was CMO of Targacept Inc. BC...
BioCentury | Sep 4, 2015
Company News

Management tracks

...Faraday Pharmaceuticals Inc. (Seattle, Wash.) named Stephen Hill CEO. Hill was president and CEO of Targacept Inc....
BioCentury | Aug 24, 2015
Company News

Catalyst Biosciences, Targacept deal

...Catalyst completed its merger with Targacept to form new company Catalyst Biosciences Inc. (see BioCentury, April...
...Catalyst Biosciences Inc. (see BioCentury, April 6). Catalyst Biosciences Inc. (NASDAQ:CBIO), South San Francisco, Calif. Targacept Inc....
BioCentury | May 11, 2015
Company News

Catalyst Biosciences, Wyeth deal

...of human coagulation Factor VIIa has completed a Phase I trial. Catalyst is merging with Targacept Inc....
Items per page:
1 - 10 of 292
BioCentury | Feb 22, 2019
Financial News

Peloton planning Phase III kidney cancer study with $150M series E

...Musso CFO. The company said Musso previously led IPOs at Bellicum Pharmaceuticals Inc. (NASDAQ:BLCM) and Targacept Inc....
BioCentury | Feb 20, 2019
Financial News

Peloton planning Phase III kidney cancer study with $150M series E

...Musso CFO. The company said Musso previously led IPOs at Bellicum Pharmaceuticals Inc. (NASDAQ:BLCM) and Targacept Inc....
BioCentury | May 4, 2018
Financial News

Attenua raises $35M series A

...neuronal nicotinic acetylcholine receptor alpha 7 (CHRNA7) agonist from Catalyst Biosciences Inc. (NASDAQ:CBIO) in 2016. Targacept Inc....
BioCentury | Apr 30, 2018
Financial News

Cough company Attenua raises $35M series A, names CEO

...neuronal nicotinic acetylcholine receptor alpha 7 (CHRNA7) agonist from Catalyst Biosciences Inc. (NASDAQ:CBIO) in 2016. Targacept Inc....
BioCentury | Oct 31, 2016
Company News

Catalyst Biosciences deal

...the products when it merged with Targacept Inc. , declined to disclose further details. Last year, Targacept...
BioCentury | Aug 22, 2016
Company News

Catalyst Biosciences, Attenua deal

...in milestones, plus royalties. Catalyst gained the products when it merged with Targacept Inc. last year. Targacept...
...treat schizophrenia and missed the primary endpoint in a Phase II trial to treat ADHD. Targacept...
...endpoint in a Phase II trial to treat Type II diabetes. Under a 2013 deal, Targacept...
BioCentury | Sep 9, 2015
Financial News

Selecta raises $38M in series E

...Particle (SVP) platform. Also on Tuesday, Selecta named Earl Sands CMO. Sands was CMO of Targacept Inc. BC...
BioCentury | Sep 4, 2015
Company News

Management tracks

...Faraday Pharmaceuticals Inc. (Seattle, Wash.) named Stephen Hill CEO. Hill was president and CEO of Targacept Inc....
BioCentury | Aug 24, 2015
Company News

Catalyst Biosciences, Targacept deal

...Catalyst completed its merger with Targacept to form new company Catalyst Biosciences Inc. (see BioCentury, April...
...Catalyst Biosciences Inc. (see BioCentury, April 6). Catalyst Biosciences Inc. (NASDAQ:CBIO), South San Francisco, Calif. Targacept Inc....
BioCentury | May 11, 2015
Company News

Catalyst Biosciences, Wyeth deal

...of human coagulation Factor VIIa has completed a Phase I trial. Catalyst is merging with Targacept Inc....
Items per page:
1 - 10 of 292